Document Detail

Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.
MedLine Citation:
PMID:  23292213     Owner:  NLM     Status:  Publisher    
Evidence supports early use of non-biologic DMARDs to prevent irreversible damage in inflammatory arthritides, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and possibly ankylosing spondylitis (AS). However, there is a paucity of data exploring their effects on pain as a primary outcome in these conditions. This systematic literature review investigated the effect of non-biologic DMARDs on pain levels in IA and examined whether disease duration impacted efficacy. We searched Medline, Embase, Cochrane Central, and Cochrane Database of Systematic Reviews, abstracts from the 2008 to 2010 American College of Rheumatology annual congresses, and citation lists of retrieved publications. Only randomized, double-blind controlled trials were analyzed. Quality was assessed with the Risk of Bias tool. Descriptive statistics were used in meta-analysis. 9,860 articles were identified, with 33 eligible for inclusion: 8 in AS, 6 in PsA, 9 in early RA (ERA), and 10 in established RA. In ERA and established RA, all studies of DMARDs (monotherapy and combination therapies) consistently revealed statistically significant reductions in pain except three oral gold studies. In AS, sulfasalazine studies showed significant pain reduction, whereas use of other DMARDs did not. In PsA, 5 of 6 studies reported VAS-pain improvement. From the studies included, we were unable to assess the influence of disease duration on pain outcomes in these rheumatic conditions. DMARDs improve pain in early and established RA. Sulfasalazine may improve pain in AS and PsA. Further study is needed to assess the relationship between disease duration and DMARD efficacy in reducing pain in these conditions.
Amanda J Steiman; Janet E Pope; Heather Thiessen-Philbrook; Lihua Li; Cheryl Barnabe; Fares Kalache; Tabitha Kung; Louis Bessette; Cathy Flanagan; Boulos Haraoui; Jacqueline Hochman; Sharon Leclercq; Dianne Mosher; Carter Thorne; Vivian Bykerk
Related Documents :
6190603 - Subcalcaneal pain. a method of evaluation and plan for treatment.
24938193 - Chronic widespread pain in spondyloarthritis.
23367023 - Development and in vitro evaluation of an artificial spinal disc loading cell.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-6
Journal Detail:
Title:  Rheumatology international     Volume:  -     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Rheumatology, Toronto Western Hospital, University of Toronto, University Health Network, 399 Bathurst Street, Room 1E-420, Toronto, ON, M5T 2S8, Canada,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A SMAD3 gene polymorphism is related with osteoarthritis in a Northeast Chinese population.
Next Document:  Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune resp...